| Scrip Code | 532331 |
|---|---|
| NSE Symbol | AJANTPHARM |
| MSEI Symbol | NOTLISTED |
| ISIN | INE031B01049 |
| Name of company | Ajanta Pharma Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 05-05-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 21-04-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Fourth quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Audited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited |
| Segment Reporting | Single segment |
| Description of single segment | PHARMACEUTICAL |
| Start date and time of board meeting | 05-05-2026 13:30:00 |
| End date and time of board meeting | 05-05-2026 15:10:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Whether the company has any related party? | Yes |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes |
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public | NA |
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | NA |
| Whether the company is a high value debt listed entity according to regulation 15 (1A)? | No |
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? | |
| (b) If answer to above question is No, please explain the reason for not complying. | |
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? | Yes |
| Latest Date on which RPT policy is updated | 30-04-2022 |
| Indicate Company website link for updated RPT policy of the Company | https://www.ajantapharma.com/assets/frontend/images/investors/files/policies_and_codes/PolicyonRelatedPartyTransactions.pdf |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No |
| No. of times funds raised during the quarter | |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| Nosuchdefault | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 1,21,053.00 | 4,84,592.00 | |
| Other income | 6,298.00 | 20,440.00 | |
| Total income | 1,27,351.00 | 5,05,032.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 25,677.00 | 91,652.00 |
| (b) | Purchases of stock-in-trade | 5,799.00 | 21,806.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (4,956.00) | (5,732.00) |
| (d) | Employee benefit expense | 31,349.00 | 1,19,405.00 |
| (e) | Finance costs | (74.00) | 259.00 |
| (f) | Depreciation, depletion and amortisation expense | 4,416.00 | 16,877.00 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 39,379.00 | 1,37,662.00 |
| Total other expenses | 39,379.00 | 1,37,662.00 | |
| Total expenses | 1,01,590.00 | 3,81,929.00 | |
| 3 | Total profit before exceptional items and tax | 25,761.00 | 1,23,103.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 25,761.00 | 1,23,103.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 6,733.00 | 27,661.00 |
| 8 | Deferred tax | (700.00) | 760.00 |
| 9 | Total tax expenses | 6,033.00 | 28,421.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 19,728.00 | 94,682.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 19,728.00 | 94,682.00 |
| 17 | Other comprehensive income net of taxes | 228.00 | (31.00) |
| 18 | Total Comprehensive Income for the period | 19,956.00 | 94,651.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 2,507.00 | 2,507.00 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | 4,19,846.00 | |
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 15.79 | 75.79 | |
| Diluted earnings (loss) per share from continuing operations | 15.79 | 75.77 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 15.79 | 75.79 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 15.79 | 75.77 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1.The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 5 May 2026. The statutory auditors have expressed an unmodified opinion on the results for the quarter and year ended 31 March 2026. The review report has been filed with the stock exchange and is available on the company’s website. 2.The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures upto the third quarter ended 31 December 2025 and 31 December 2024 respectively. 3.Other income includes: (Rs. in Crores) Quarter ended Year ended 31.03.26 31.12.25 31.03.25 31.03.26 31.03.25 Dividend from subsidiaries - - - 36.68 22.28 Foreign exchange gain 46.16 9.42 7.29 99.66 32.96 (in other income) Foreign exchange loss 41.70 - - 103.04 8.82 (in other expenses) 4.During the yearended 31 march 2026, 23,525 (previous year 25,325) equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by Rs. 47,050 (previous year Rs. 50,650) and securities premium by Rs. 3.50 crores (previous year Rs. 3.84 crores).Under the same plan, 4,300 Cash Settled Stock Appreciation Rights (SARs) were vested and settled in cash and there was no change in the paid-up share capital and securities premium of the company. 5. In August 2025, the Income Tax Authorities carried out search operations at certain premises of the Company. Subsequently, the Company received a notice dated 6 February 2026 under Section 158BC of the Income tax Act, 1961, requiring the Company to file a true and correct return of undisclosed income for the block period from 1 April 2019 to 17 November 2025. The Company filed the return for the said block period on 6 April 2026, without reporting any undisclosed income. Pending any subsequent communication from the concerned authorities in this regard, the consequent impact on the standalone financial result for the year ended 31 March 2026, if any, is currently not ascertainable. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | |
|---|---|---|
| Date of start of reporting period | 01-04-2025 | |
| Date of end of reporting period | 31-03-2026 | |
| Whether results are audited or unaudited | Audited | |
| Nature of report standalone or consolidated | Standalone | |
| Assets | ||
| 1 | Non-current assets | |
| Property, plant and equipment | 1,72,263.00 | |
| Capital work-in-progress | 25,805.00 | |
| Investment property | 0.00 | |
| Goodwill | 0.00 | |
| Other intangible assets | 12,214.00 | |
| Intangible assets under development | 0.00 | |
| Biological assets other than bearer plants | 0.00 | |
| Investments accounted for using equity method | 0.00 | |
| Non-current financial assets | ||
| Non-current investments | 4,639.00 | |
| Trade receivables, non-current | 0.00 | |
| Loans, non-current | 0.00 | |
| Other non-current financial assets | ||
| 1 | Other non-current financial assets | 617.00 |
| Total of other non-current financial assets | 617.00 | |
| Total non-current financial assets | 5,256.00 | |
| Deferred tax assets (net) | 0.00 | |
| Other non-current assets | ||
| 1 | Other non-current assets | 3,711.00 |
| 2 | Non current tax assets (net) | 557.00 |
| Total of other non-current assets | 4,268.00 | |
| Total non-current assets | 2,19,806.00 | |
| 2 | Current assets | |
| Inventories | 84,471.00 | |
| Current financial asset | ||
| Current investments | 55,985.00 | |
| Trade receivables, current | 1,36,577.00 | |
| Cash and cash equivalents | 8,904.00 | |
| Bank balance other than cash and cash equivalents | 151.00 | |
| Loans, current | 168.00 | |
| Other current financial assets | ||
| Total of other current financial assets | 898.00 | |
| Total current financial assets | 2,02,683.00 | |
| Current tax assets (net) | 0.00 | |
| Other current assets | ||
| 1 | Other current assets | 24,712.00 |
| Total of other current assets | 24,712.00 | |
| Total current assets | 3,11,866.00 | |
| 3 | Non-current assets classified as held for sale | 0.00 |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | 0.00 |
| Total assets | 5,31,672.00 | |
| Equity and liabilities | ||
| 1 | Equity | |
| Equity attributable to owners of parent | ||
| Equity share capital | 2,507.00 | |
| Other equity | 4,19,846.00 | |
| Total equity attributable to owners of parent | 4,22,353.00 | |
| Non controlling interest | ||
| Total equity | 4,22,353.00 | |
| 2 | Liabilities | |
| Non-current liabilities | ||
| Non-current financial liabilities | ||
| Borrowings, non-current | 0.00 | |
| Trade payables, non-current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 0.00 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 0.00 | |
| Total Trade payable | 0.00 | |
| Other non-current financial liabilities | ||
| 1 | Other non-current financial liabilities | 182.00 |
| 2 | Lease liabilities | 2,958.00 |
| Total of other non-current financial liabilities | 3,140.00 | |
| Total non-current financial liabilities | 3,140.00 | |
| Provisions, non-current | 5,115.00 | |
| Deferred tax liabilities (net) | 11,794.00 | |
| Deferred government grants, Non-current | 167.00 | |
| Other non-current liabilities | ||
| Total of other non-current liabilities | ||
| Total non-current liabilities | 20,216.00 | |
| Current liabilities | ||
| Current financial liabilities | ||
| Borrowings, current | 0.00 | |
| Trade payables, current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 5,417.00 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 41,768.00 | |
| Total Trade payable | 47,185.00 | |
| Other current financial liabilities | ||
| 1 | Other current financial liabilities | 25,919.00 |
| 2 | Lease liabilities | 511.00 |
| Total of other current financial liabilities | 26,430.00 | |
| Total current financial liabilities | 73,615.00 | |
| Other current liabilities | 11,900.00 | |
| 1 | Other current liabilities | 11,900.00 |
| Total of other current liabilities | 11,900.00 | |
| Provisions, current | 3,039.00 | |
| Current tax liabilities (Net) | 549.00 | |
| Deferred government grants, Current | 0.00 | |
| Total current liabilities | 89,103.00 | |
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | 0.00 |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | 0.00 |
| Total liabilities | 1,09,319.00 | |
| Total equity and liabilites | 5,31,672.00 | |
| Disclosure of notes on assets and liabilities | ||
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-01-2026 | 01-04-2025 | |||||
| Date of end of reporting period | 31-03-2026 | 31-03-2026 | |||||
| Whether results are audited or unaudited | Audited | Audited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Re-measurement of defined benefit liability/(assets) | 351.00 | (48.00) |
| Total Amount of items that will not be reclassified to profit and loss | 351.00 | (48.00) | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 123.00 | (17.00) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | ||
| 5 | Total Other comprehensive income | 228.00 | (31.00) |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 31-03-2026 | ||||
| C | Whether results are audited or unaudited | Audited | ||||
| D | Nature of report standalone or consolidated | Standalone | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 1,23,103.00 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 259.00 | |||||
| Adjustments for decrease (increase) in inventories | (10,542.00) | |||||
| Adjustments for decrease (increase) in trade receivables, current | (7,761.00) | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | (13,617.00) | |||||
| Adjustments for decrease (increase) in other non-current assets | 0.00 | |||||
| Adjustments for other financial assets, non-current | 0.00 | |||||
| Adjustments for other financial assets, current | 0.00 | |||||
| Adjustments for other bank balances | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, current | 10,369.00 | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | (537.00) | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0.00 | |||||
| Adjustments for depreciation and amortisation expense | 16,877.00 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 376.00 | |||||
| Adjustments for provisions, current | (2,239.00) | |||||
| Adjustments for provisions, non-current | 0.00 | |||||
| Adjustments for other financial liabilities, current | 0.00 | |||||
| Adjustments for other financial liabilities, non-current | 0.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | (5,814.00) | |||||
| Adjustments for dividend income | 3,668.00 | |||||
| Adjustments for interest income | 5,974.00 | |||||
| Adjustments for share-based payments | 153.00 | |||||
| Adjustments for fair value losses (gains) | 8,737.00 | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | 0.00 | |||||
| Other adjustments to reconcile profit (loss) | 0.00 | |||||
| Other adjustments for non-cash items | (33.00) | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | (13,414.00) | |||||
| Net cash flows from (used in) operations | 1,09,689.00 | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | 29,306.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | 80,383.00 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 0.00 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 2,54,910.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 2,65,998.00 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 326.00 | |||||
| Proceeds from sales of property, plant and equipment | 50.00 | |||||
| Purchase of property, plant and equipment | 36,728.00 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 0.00 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 3,668.00 | |||||
| Interest received | 4,481.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | (12.00) | |||||
| Net cash flows from (used in) investing activities | (39,955.00) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 0.00 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 0.00 | |||||
| Repayments of borrowings | 0.00 | |||||
| Payments of lease liabilities | 963.00 | |||||
| Dividends paid | 34,972.00 | |||||
| Interest paid | 27.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) financing activities | (35,962.00) | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 4,466.00 | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | (421.00) | |||||
| Net increase (decrease) in cash and cash equivalents | 4,045.00 | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 4,860.00 | |||||
| Cash and cash equivalents cash flow statement at end of period | 8,905.00 | |||||
| Whether results are audited or unaudited | Audited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | B S R & Co. LLP | Yes | 31-07-2025 | ||
|---|---|---|---|---|---|
Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) |
| Sr No. | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. | ||||||||||||||||||||||||
| Details of the party (listed entity/subsidiary) entering into the transaction | Details of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments | Notes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment ) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | ||||||||||
| 1 | Ajanta Pharma Limited | Ajanta Foundation | Company is able to exercise significant control over this entity | Any other transaction | Corporate Social Responsibility expense | Transactions are carried out on arms length basis and in ordinary course of business | 37.00 | 0.00 | 0.00 | ||||||||||||||||
| 2 | Ajanta Pharma Limited | A I Printers | Relative of Chairman | Purchase of goods or services | Transactions are carried out on arms length basis and in ordinary course of business | 696.00 | 0.00 | 0.00 | |||||||||||||||||
| 3 | Ajanta Pharma Limited | A I Printers | Relative of Chairman | Any other transaction | Trade Payable | Transactions are carried out on arms length basis and in ordinary course of business | 0.00 | 111.00 | 245.00 | ||||||||||||||||
| 4 | Ajanta Pharma Limited | Ajanta Pharma (Mauritius) Ltd | Subsidiary | Sale of goods or services | N.A. | 5,019.00 | 0.00 | 0.00 | |||||||||||||||||
| 5 | Ajanta Pharma Limited | Ajanta Pharma (Mauritius) Ltd | Subsidiary | Any other transaction | Trade Receivable | N.A. | 0.00 | 3,622.00 | 282.00 | ||||||||||||||||
| 6 | Ajanta Pharma Limited | Ajanta Pharma (Mauritius) Ltd | Subsidiary | Investment | N.A. | 0.00 | 944.00 | 944.00 | |||||||||||||||||
| 7 | Ajanta Pharma Limited | Ajanta Pharma Nigeria Ltd | Subsidiary | Any other transaction | Reimbursement of expenses | N.A. | 21.00 | 0.00 | 0.00 | ||||||||||||||||
| 8 | Ajanta Pharma Limited | Ajanta Pharma Nigeria Ltd | Subsidiary | Any other transaction | Advance given | N.A. | 0.00 | 12.00 | 1.00 | ||||||||||||||||
| 9 | Ajanta Pharma Limited | Ajanta Pharma Nigeria Ltd | Subsidiary | Investment | N.A. | 0.00 | 137.00 | 137.00 | |||||||||||||||||
| 10 | Ajanta Pharma Limited | Ajanta Pharma Nigeria Ltd | Subsidiary | Any other transaction | Impairment of Investment in Subsidiary | N.A. | 0.00 | (137.00) | (137.00) | ||||||||||||||||
| 11 | Ajanta Pharma Limited | Ajanta Pharma Philippines Inc. | Subsidiary | Sale of goods or services | Transactions are carried out on arms length basis and in ordinary course of business | 8,894.00 | 0.00 | 0.00 | |||||||||||||||||
| 12 | Ajanta Pharma Limited | Ajanta Pharma Philippines Inc. | Subsidiary | Any other transaction | Trade Receivable | N.A. | 0.00 | 10,543.00 | 9,545.00 | ||||||||||||||||
| 13 | Ajanta Pharma Limited | Ajanta Pharma Philippines Inc. | Subsidiary | Investment | N.A. | 0.00 | 138.00 | 138.00 | |||||||||||||||||
| 14 | Ajanta Pharma Limited | Ajanta Pharma USA Inc. | Subsidiary | Sale of goods or services | Transactions are carried out on arms length basis and in ordinary course of business | 59,685.00 | 0.00 | 0.00 | |||||||||||||||||
| 15 | Ajanta Pharma Limited | Ajanta Pharma USA Inc. | Subsidiary | Any other transaction | Trade Receivable | N.A. | 0.00 | 53,976.00 | 72,469.00 | ||||||||||||||||
| 16 | Ajanta Pharma Limited | Ajanta Pharma USA Inc. | Subsidiary | Any other transaction | Shared services | N.A. | 115.00 | 0.00 | 0.00 | ||||||||||||||||
| 17 | Ajanta Pharma Limited | Ajanta Pharma USA Inc. | Subsidiary | Any other transaction | Other Receivables | N.A. | 0.00 | 52.00 | 61.00 | ||||||||||||||||
| 18 | Ajanta Pharma Limited | Ajanta Pharma USA Inc. | Subsidiary | Investment | N.A. | 0.00 | 707.00 | 707.00 | |||||||||||||||||
| 19 | Ajanta Pharma Limited | Arvind Agrawal | Chief Financial Officer & KMP | Remuneration | N.A. | 120.00 | 0.00 | 0.00 | |||||||||||||||||
| 20 | Ajanta Pharma Limited | Arvind Agrawal | Chief Financial Officer & KMP | Remuneration | N.A. | 13.00 | 0.00 | 0.00 | |||||||||||||||||
| 21 | Ajanta Pharma Limited | Arvind Agrawal | Chief Financial Officer & KMP | Remuneration | N.A. | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| 22 | Ajanta Pharma Limited | Arvind Agrawal | Chief Financial Officer & KMP | Dividend paid | N.A. | 5.00 | 0.00 | 0.00 | |||||||||||||||||
| 23 | Ajanta Pharma Limited | David Paul Rasquinha | Independent Director | Any other transaction | Sitting fees paid | N.A. | 3.00 | 0.00 | 0.00 | ||||||||||||||||
| 24 | Ajanta Pharma Limited | David Paul Rasquinha | Independent Director | Any other transaction | Commission payable | N.A. | 2.00 | 3.00 | 5.00 | ||||||||||||||||
| 25 | Ajanta Pharma Limited | Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal | Promoter | Dividend paid | N.A. | 938.00 | 0.00 | 0.00 | |||||||||||||||||
| 26 | Ajanta Pharma Limited | Gaurang Shah | Company Secretary & KMP | Remuneration | N.A. | 60.00 | 0.00 | 0.00 | |||||||||||||||||
| 27 | Ajanta Pharma Limited | Gaurang Shah | Company Secretary & KMP | Remuneration | N.A. | 4.00 | 0.00 | 0.00 | |||||||||||||||||
| 28 | Ajanta Pharma Limited | Gaurang Shah | Company Secretary & KMP | Remuneration | N.A. | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| 29 | Ajanta Pharma Limited | Gaurang Shah | Company Secretary & KMP | Dividend paid | N.A. | 1.00 | 0.00 | 0.00 | |||||||||||||||||
| 30 | Ajanta Pharma Limited | Madhusudan B. Agrawal | Executive Vice-Chairman | Remuneration | N.A. | 264.00 | 0.00 | 0.00 | |||||||||||||||||
| 31 | Ajanta Pharma Limited | Madhusudan B. Agrawal | Executive Vice-Chairman | Remuneration | N.A. | 11.00 | 0.00 | 0.00 | |||||||||||||||||
| 32 | Ajanta Pharma Limited | Mannalal B. Agrawal | Non Executive Director - Chairman | Any other transaction | Sitting fees paid | N.A. | 5.00 | 0.00 | 0.00 | ||||||||||||||||
| 33 | Ajanta Pharma Limited | Medha Vinay Joshi | Independent Director | Any other transaction | Sitting fees paid | N.A. | 4.00 | 0.00 | 0.00 | ||||||||||||||||
| 34 | Ajanta Pharma Limited | Medha Vinay Joshi | Independent Director | Any other transaction | Commission payable | N.A. | 1.00 | 2.00 | 3.00 | ||||||||||||||||
| 35 | Ajanta Pharma Limited | Rajesh M Agrawal, trustee Rajesh Agrawal Trust� | Promoter | Dividend paid | N.A. | 5,062.00 | 0.00 | 0.00 | |||||||||||||||||
| 36 | Ajanta Pharma Limited | Rajesh M. Agrawal | Joint Managing Director & KMP | Remuneration | N.A. | 852.00 | 0.00 | 0.00 | |||||||||||||||||
| 37 | Ajanta Pharma Limited | Rajesh M. Agrawal | Joint Managing Director & KMP | Remuneration | N.A. | 63.00 | 0.00 | 0.00 | |||||||||||||||||
| 38 | Ajanta Pharma Limited | Rajesh M. Agrawal | Joint Managing Director & KMP | Any other transaction | Commission payable | N.A. | 550.00 | 500.00 | 1,050.00 | ||||||||||||||||
| 39 | Ajanta Pharma Limited | Rajesh S Dalal | Independent Director | Any other transaction | Sitting fees paid | N.A. | 5.00 | 0.00 | 0.00 | ||||||||||||||||
| 40 | Ajanta Pharma Limited | Rajesh S Dalal | Independent Director | Any other transaction | Commission payable | N.A. | 1.00 | 2.00 | 3.00 | ||||||||||||||||
| 41 | Ajanta Pharma Limited | Samta Foundation | Promoter group is able to exercise significant control over this entity | Any other transaction | Corporate Social Responsibility expense | Transactions are carried out on arms length basis and in ordinary course of business | 235.00 | 0.00 | 0.00 | ||||||||||||||||
| 42 | Ajanta Pharma Limited | Simi Manohar Lal Thapar | Independent Director | Any other transaction | Sitting fees paid | N.A. | 5.00 | 0.00 | 0.00 | ||||||||||||||||
| 43 | Ajanta Pharma Limited | Simi Manohar Lal Thapar | Independent Director | Any other transaction | Commission payable | N.A. | 1.00 | 2.00 | 3.00 | ||||||||||||||||
| 44 | Ajanta Pharma Limited | Tanya Agrawal | Daughter of Managing Director | Remuneration | N.A. | 8.00 | 0.00 | 0.00 | |||||||||||||||||
| 45 | Ajanta Pharma Limited | Tanya Agrawal | Daughter of Managing Director | Remuneration | N.A. | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| 46 | Ajanta Pharma Limited | Yash Agrawal | Son of Managing Director | Remuneration | N.A. | 4.00 | 0.00 | 0.00 | |||||||||||||||||
| 47 | Ajanta Pharma Limited | Yash Agrawal | Son of Managing Director | Remuneration | N.A. | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| 48 | Ajanta Pharma Limited | Yogesh M Agrawal, trustee Yogesh Agrawal Trust� | Promoter | Dividend paid | N.A. | 5,062.00 | 0.00 | 0.00 | |||||||||||||||||
| 49 | Ajanta Pharma Limited | Yogesh M. Agrawal | Managing Director & KMP | Remuneration | N.A. | 852.00 | 0.00 | 0.00 | |||||||||||||||||
| 50 | Ajanta Pharma Limited | Yogesh M. Agrawal | Managing Director & KMP | Remuneration | N.A. | 61.00 | 0.00 | 0.00 | |||||||||||||||||
| 51 | Ajanta Pharma Limited | Yogesh M. Agrawal | Managing Director & KMP | Any other transaction | Commission payable | N.A. | 550.00 | 500.00 | 1,050.00 | ||||||||||||||||
| 52 | Ajanta Pharma Limited | Credible Innovations Private Limited | Relative of Chairman | Purchase of goods or services | Transactions are carried out on arms length basis and in ordinary course of business | 8.00 | 0.00 | 0.00 | |||||||||||||||||
| 53 | Ajanta Pharma Limited | Ravi P Agrawal, trustee Ravi Agrawal Trust | Promoter | Dividend paid | N.A. | 4,548.00 | 0.00 | 0.00 | |||||||||||||||||
| 54 | Ajanta Pharma Limited | Ravi P Agrawal | Promoter | Dividend paid | N.A. | 80.00 | 0.00 | 0.00 | |||||||||||||||||
| 55 | Ajanta Pharma Limited | Aayush M Agrawal, trustee Aayush Agrawal Trust | Promoter | Dividend paid | N.A. | 3,952.00 | 0.00 | 0.00 | |||||||||||||||||
| 56 | Ajanta Pharma Limited | Aayush M Agrawal | Promoter | Dividend paid | N.A. | 8.00 | 0.00 | 0.00 | |||||||||||||||||
| 57 | Ajanta Pharma Limited | Gabs Investments Pvt Ltd | Promoter | Dividend paid | N.A. | 3,525.00 | 0.00 | 0.00 | |||||||||||||||||
| 58 | Ajanta Pharma Limited | M/s. AI Packaging | Relative of Chairman | Purchase of goods or services | Transactions are carried out on arms length basis and in ordinary course of business | 497.00 | 0.00 | 0.00 | |||||||||||||||||
| 59 | Ajanta Pharma Limited | M/s. AI Packaging | Relative of Chairman | Any other transaction | Trade Payable | Transactions are carried out on arms length basis and in ordinary course of business | 0.00 | 77.00 | 91.00 | ||||||||||||||||
| 60 | Ajanta Pharma Limited | Veer Agrawal | Son of Managing Director | Remuneration | N.A. | 4.00 | 0.00 | 0.00 | |||||||||||||||||
| 61 | Ajanta Pharma Limited | Veer Agrawal | Son of Managing Director | Remuneration | N.A. | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| 62 | Ajanta Pharma Limited | CSI Renting India Private Limited | Relative of Chairman | Purchase of goods or services | Transactions are carried out on arms length basis and in ordinary course of business | 58.00 | 0.00 | 0.00 | |||||||||||||||||
| 63 | Ajanta Pharma Limited | CSI Renting India Private Limited | Relative of Chairman | Any other transaction | Trade Payable | Transactions are carried out on arms length basis and in ordinary course of business | 0.00 | 0.00 | 26.00 | ||||||||||||||||
| 64 | Ajanta Pharma Limited | Seva Home Collectionn Pvt Ltd | Company is able to exercise significant control over this entity | Purchase of goods or services | Transactions are carried out on arms length basis and in ordinary course of business | 5.00 | 0.00 | 1.00 | |||||||||||||||||
| 65 | Ajanta Pharma Limited | David Paul Rasquinha | Independent Director | Dividend paid | N.A. | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| 66 | Ajanta Pharma Limited | Seth Bhagwandas Charitable Trust | Promoter group is able to exercise significant control over this entity | Any other transaction | Corporate Social Responsibility expense | Transactions are carried out on arms length basis and in ordinary course of business | 5.00 | 0.00 | 0.00 | ||||||||||||||||
| Total value of transaction during the reporting period | 1,01,899.00 | ||||||||||||||||||||||||